Slide 1: Medios 9M/Q3 2020 Results
Medios 9M/Q3 2020 Results Matthias Gaertner, CFO 12 November 2020
Slide 2: Agenda
Agenda • Executive Summary Financial Overview Guidance 2020 Appendix 2
Slide 3: Highlights 2020 year-to-date – Growth strategy on track
Highlights 2020 year-to-date – Growth strategy on track Growth strategy on track • Pharmaceutical Supply: • continues to be a clear growth driver, however, growth weakened at lower margins as a result of the COVID-19 pandemic • new indication: hemophilia • Patient-specific Therapies: OPERATIONS • pe
Slide 4: Dynamic growth despite COVID-19 Pandemic
Dynamic growth despite COVID-19 Pandemic Continuation of growth strategy: Business model intact Revenue €m EBITDA pre* €m EBT pre* €m 453 14.1 12.8 372 10.2 8.0 9M 2019 9M 2020 9M 2019 9M 2020 9M 2019 9M 2020 Corona-related effects continued in the second half of the year • First quarter saw extensi
Slide 5: Q3 2020 vs. Q2 2020: Overview Key Figures
Q3 2020 vs. Q2 2020: Overview Key Figures Revenue €m EBITDA pre* €m EBT pre* €m Comments • Revenue for Q2 and Q3 affected by COVID-19- related effects • Revenue increase mainly driven by wholesale business • Operating results impacted by procurement issues 160.0 3.1 130.1 3.8 2.2 1.2 Q2 2020 Q3 2020
Slide 6: Business model intact: Proven growth strategy in place with growth prospects
Business model intact: Proven growth strategy in place with growth prospects VERTICAL GROWTH DRIVER HORIZONTAL GROWTH DRIVER PROFITABILITY DRIVER Grow customer base and Extend product range and expand to partner network further indication areas Leverage economies of scale • Currently ~330 pharmacies
Slide 7: New management structure effective 1 January 2021
New management structure effective 1 January 2021 Executive Board Supervisory Board Deputy Chairman COO CINO Chairman Member Chairman Matthias Mi-Young Christoph Dr. Yann Joachim Klaus J. Gärtner Miehler Prußeit Samson Messner Buß Advisory Board: establishment in 2021 Member Member Member ..….. Manf
Slide 8: Agenda
Agenda Executive Summary • Financial Overview Guidance 2020 Appendix 8
Slide 9: 9M 2020 Group: Financials affected by COVID-19-effects
9M 2020 Group: Financials affected by COVID-19-effects In € million 9M 2020 9M 2019 ∆% Comments Revenue 452.9 371.7 21.9 • Strong revenue growth, Pharmaceutical Supply key contributor (Kölsche Blister COGS* 426.7 348.1 22.6 included with €3.5m revenue for Q2 & ratio in % of revenue 94.2% 93.7% Q3) P
Slide 10: 9M 2020 Segments – Growth driven by wholesale business
9M 2020 Segments – Growth driven by wholesale business Patient-specific Internal Services and Pharmaceutical Supply Group Therapies IFRS consolidation In € million 9M 2020 9M 2019 9M 2020 9M 2019 9M 2020 9M 2019 9M 2020 9M 2019 Revenue (external) 406.0 333.9 46.5 37.6 0.3 0.2 452.9 371.7 Delta (y-o-
Slide 11: Financing Power – Strong financial position to invest in future growth
Financing Power – Strong financial position to invest in future growth As of 30 September In € million Comments Syndicated loan 62.5 Organic growth • High single-digit million € range to Thereof called/drawn -1.5 be invested in own labs External growth Cash & cash equivalents 67.3 • M&A strategy: fo
Slide 12: Agenda
Agenda Executive summary Financial Overview • Guidance 2020 Appendix 12
Slide 13: Guidance for full-year 2020 confirmed
Guidance for full-year 2020 confirmed In € million 2020e Group revenue 610 - 630 Adj. EBITDA* 14.0 – 15.0 Adj. EBT* 11.5 – 12.5 Adj. EBT* margin (in %) 1.9 – 2.0 Reach the 1 billion € revenue mark by 2023 at the latest * EBITDA and EBT without extraordinary expenses: adjusted for extraordinary expen
Slide 14: Proven financial track with strong profitable growth
Proven financial track with strong profitable growth Medios Group IFRS 2015*1 2016*1 2017*2 2018*2 2019*2 2020E*2, 4 2023E 1,000 Pharmaceutical Supply Patient–specific Therapies 610-630 517 10% 328 254 12% 160 17% 90% 90 25% 88% 38% 83% Revenue in € m 75% 62% Pharmaceutical Supply Patient–specific T
Slide 15: Goals for 2021 – Ongoing growth strategy
Goals for 2021 – Ongoing growth strategy • Organic growth • Expansion of manufacturing capacities – completion of new laboratories in Berlin • Further establishment of “blistering“ in Germany • Expansion of partner network of specialized pharmacies • Preparation of e-prescriptions launch on 1 Januar
Slide 16: Appendix
OS AG Appendix PHARMA SOLUTIONS - 1 E * | s > rf
Slide 17: Q3 2020 Group: Financials
Q3 2020 Group: Financials In € million Q3 2020 Q3 2019 ∆% Comments Revenue 160.0 143.2 11.8 • Strong revenue growth, Pharmaceutical Supply key contributor (Kölsche Blister COGS* 151.3 134.1 12.8 included with the second & third ratio in % of revenue 94.5% 93.7% quarter) Personnel expenses 3.8 2.7 42
Slide 18: Q3 2020 Segments – Growth driven by wholesale business
Q3 2020 Segments – Growth driven by wholesale business Patient-specific Internal Services and Pharmaceutical Supply Group Therapies IFRS consolidation In € million Q3 2020 Q3 2019 Q3 2020 Q3 2019 Q3 2020 Q3 2019 Q3 2020 Q3 2019 Revenue (external) 144.0 129.7 15.9 13.4 0.1 0.1 160.0 143.2 Delta (y-o-
Slide 19: Consolidated statement of comprehensive income 9M/Q3 2020
Consolidated statement of comprehensive income 9M/Q3 2020 impacted by COVID-19 pandemic and additional one-time effects In € thousand 9M 2020 9M 2019 Q3 2020 Q3 2019 Revenue 452,900 371,679 160,015 143,172 Change in stocks of finished goods and work-in- 45 462 32 440 progress Work performed and capi
Slide 20: Consolidated Balance Sheets 9M 2020
Consolidated Balance Sheets 9M 2020 ASSETS LIABILITIES In € thousand 30/09/2020 31/12/2019 In € thousand 30/09/2020 31/12/2019 Equity Non-current assets 45,548 37,136 Subscribed capital 16,085 14,564 Intangible assets 34,391 31,260 Capital reserves 103,828 51,273 Accumulated Group Result 20,058 15,7
Slide 21: Consolidated cash flow statement 9M/Q3 2020
Consolidated cash flow statement 9M/Q3 2020 In € thousand 9M 2020 9M 2019 Q3 2020 Q3 2019 Cash flow from operating activities Net income for the year 4,269 7,958 1,101 3,987 Depreciation and amortization on non-current assets 2,568 1,623 947 519 Decrease/increase in provisions -114 -50 -6 81 Other n
Slide 22: IR Contact
IR Contact Claudia Nickolaus Head of Investor & Public Relations Phone: +49 30 232 5668 00 E-mail: ir@medios.ag 22
Slide 23: Disclaimer
Disclaimer This presentation has been produced by Medios AG (the „Company“). The facts and The forward-looking statements, including but not limited to assumptions, opinions and information contained herein are as up to date as is reasonably possible and are subject views of the Company or informati
Slide 24: Medios 9M/Q3 2020 Results
Medios 9M/Q3 2020 Results Matthias Gaertner, CFO 12 November 2020